enVVeno Medical closed at $7.00 on Nov 4, down 2.43%, 71.8% below its 52-week closing high. Volume of 63.8K shares was 1.42× its 20-day average (above normal).
Split-adjusted performance: -14.6% over one month, -30.5% over six months.
Short interest was 11.8K shares at the Oct 15 settlement, down 12.9% from the prior report (2.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NVNOenVVeno Medical | $7.00 | −2.43% | −30.5% | — | — | — | $4.9M | |
| TNONTenon Medical | $1.91 | +1.06% | −92.7% | +126.8% | −316.7% | — | $5.1M | Compare |
| SNOASonoma Pharmaceuticals | $1.11 | −2.63% | −6.7% | +59.6% | −5.2% | — | $5.3M | Compare |
| AEMDAETHLON MEDICAL | $5.75 | −0.86% | −51.7% | — | — | — | $4.1M | Compare |
| INBSIntelligent Bio Solutions | $1.75 | −1.13% | −27.4% | +35.8% | −341.0% | — | $5.8M | Compare |
| CNSYCerenome | $0.8916 | −31.42% | — | — | — | — | $6.8M | Compare |
| CODXCo-Diagnostics | $0.3614 | −4.89% | — | +2.0% | −3782.4% | — | $3.2M | Compare |
| AMIXAutonomix Medical | $1.61 | −3.01% | −80.1% | — | — | — | $3.2M | Compare |
| NMTCNeuroOne Medical Technologies | $0.9500 | −3.06% | −77.9% | +16.3% | −101.7% | — | $8.7M | Compare |
No recent articles focused on enVVeno Medical.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
